Erlotinib Completed Phase 1 Trials for Triple Negative Breast Cancer (TNBC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00998036Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors